Clinical trial to test new combination therapy against blood cancer

Wants to prolong the survival of AML patients by combining two drugs: Professor Dr. Michael Heuser Copyright: MHH / Karin Kaiser The MHH is looking for subjects with an IDH1 gene mutation for a multicenter study on the combination therapy of two drugs previously used individually against acute myeloid leukemia (AML) 28. Acute myeloid leukemia (AML) is a malignant disease in which the precursor cells of the hematopoietic system proliferate uncontrollably. This form of blood cancer is caused by genetic changes in the bone marrow that occur in the course of life. It is therefore mainly older people who are affected. If left untreated, AML leads to death within a few weeks. Already last year, an international study with the participation of Michael Heuser, Senior Physician at the Department of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation at the Hannover Medical School (MHH), showed that the combination of two drugs previously used individually against AML triples the survival time of AML patients. Now the hematologist wants to investigate a similar approach in a new multicenter study.